LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate
As California virus cases fall, more people than ever dying
30 January 2021Single virus case sends Australia’s Perth into snap lockdown
31 January 2021LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate
Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
